Literature DB >> 29516114

[Acute emergencies in oncology].

D Nashan1, S Dengler2.   

Abstract

The spectrum of dermato-oncological emergencies is multifaceted. They are particularly observed in cases with malignant melanoma due to the large number of patients and prolonged survival rates that are associated with new therapies for advanced disease. Dermato-oncological patients present to the hospital with symptoms like nausea and emesis, unexpected neurological deficits, various gastrointestinal problems, and even acute abdomen, acute breathlessness, or hemoptysis. Furthermore, emergencies can be caused by hematological problems like anemia and leukopenia. In addition to standardized care for medical emergencies, there are many other problems caused by metastases and/or therapeutic side effects that need interdisciplinary skills to optimize procedures and deliberate on surgical interventions, radiotherapy, and medical therapeutic choices with regard to the overall situation of the patient. The article deals with a spectrum of acute organ-specific emergencies, including recommendations for medical treatment and considerations for therapeutic decisions. Recommendations for supportive care in patients who are severely ill are summarized. In addition to stage-adapted pain therapy, supportive measures such as nutritional supplementation, the use of dronabinol in cases of loss of appetite, and antipruritic therapies are outlined. This article provides a succinct summary of the most frequently observed dermato-oncological emergencies with references to the respective detailed literature of associated medical societies and guidelines.

Entities:  

Keywords:  Dermato-oncology; Emergency; Emergency care; Malignant melanoma; Supportive care

Mesh:

Year:  2018        PMID: 29516114     DOI: 10.1007/s00105-018-4141-6

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  16 in total

1.  [German S 3-guideline "ascites, spontaneous bacterial peritonitis, hepatorenal syndrome"].

Authors:  A L Gerbes; V Gülberg; T Sauerbruch; R Wiest; B Appenrodt; M J Bahr; M M Dollinger; M Rössle; M Schepke
Journal:  Z Gastroenterol       Date:  2011-06-01       Impact factor: 2.000

2.  S3-Leitlinie Diagnostik, Therapie und Nachsorge des Melanoms - Update 2015/2016, Kurzversion 2.0.

Authors:  Thomas K Eigentler; Corinna Mühlenbein; Markus Follmann; Dirk Schadendorf; Claus Garbe
Journal:  J Dtsch Dermatol Ges       Date:  2017-06       Impact factor: 5.584

Review 3.  The Diagnosis and Treatment of Hemoptysis.

Authors:  Harald Ittrich; Maximilian Bockhorn; Hans Klose; Marcel Simon
Journal:  Dtsch Arztebl Int       Date:  2017-06-05       Impact factor: 5.594

4.  Improved survival with pulmonary metastasectomy: an analysis of 1720 patients with pulmonary metastatic melanoma.

Authors:  Rebecca P Petersen; Steven I Hanish; John C Haney; Charles C Miller; William R Burfeind; Douglas S Tyler; Hilliard F Seigler; Walter Wolfe; Thomas A D'Amico; David H Harpole
Journal:  J Thorac Cardiovasc Surg       Date:  2007-01       Impact factor: 5.209

5.  [Dronabinol for supportive therapy in patients with malignant melanoma and liver metastases].

Authors:  M Zutt; H Hänssle; S Emmert; C Neumann; L Kretschmer
Journal:  Hautarzt       Date:  2006-05       Impact factor: 0.751

6.  Analysis of 945 cases of pulmonary metastatic melanoma.

Authors:  D H Harpole; C M Johnson; W G Wolfe; S L George; H F Seigler
Journal:  J Thorac Cardiovasc Surg       Date:  1992-04       Impact factor: 5.209

Review 7.  [Melanoma brain metastases : Treatment options].

Authors:  R Rauschenberg; G Tabatabai; E G C Troost; M Garzarolli; S Beissert; F Meier
Journal:  Hautarzt       Date:  2016-07       Impact factor: 0.751

Review 8.  Bisphosphonates for the relief of pain secondary to bone metastases.

Authors:  R Wong; P J Wiffen
Journal:  Cochrane Database Syst Rev       Date:  2002

Review 9.  Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials.

Authors:  B El Osta; F Hu; R Sadek; R Chintalapally; S-C Tang
Journal:  Crit Rev Oncol Hematol       Date:  2017-09-08       Impact factor: 6.312

Review 10.  Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel.

Authors:  M Aapro; P A Abrahamsson; J J Body; R E Coleman; R Colomer; L Costa; L Crinò; L Dirix; M Gnant; J Gralow; P Hadji; G N Hortobagyi; W Jonat; A Lipton; A Monnier; A H G Paterson; R Rizzoli; F Saad; B Thürlimann
Journal:  Ann Oncol       Date:  2007-09-28       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.